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and 2.13 [1.75 - 2.59] in G3 compared to G1. In multivariate analysis, pain at random-
ization was the strongest predictor of poor OS: HR 1.71, 95% CI 1.39-2.11, vs PSA pro-
gression only. Other significant prognostic factors included older age, high alkaline
phosphatase, short duration of first androgen deprivation therapy, low hemoglobin
level and high neutrophil-lymphocyte ratio. Docetaxel led to 50% decline in PSA in
67.5%, 80.5% and 77% in G1, G2 and G3 respectively.
Conclusions: The type of progression at initiation of first-line chemotherapy in
mCRPC is prognostic. Patients with pain at initiation of chemotherapy had a median
OS of1 year shorter than those having PSA progression only. Validation of these
results by an independent dataset (TAX 327) is ongoing. Results will be presented at
ESMO.
Legal entity responsible for the study: Sanofi.
Funding: Sanofi.
Disclosure: R.J. van Soest: Honoraria: Astellas, Sanofi, Janssen. I.F. Tannock: Data
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Astellas. B. Tombal: Advisor, investigator: Sanofi-aventis; Janssen Pharmaceuticals,
Inc., Takeda, Astellas, Pharma, Inc., Kyocyt. M. Eisenberger: Consultancy: Sanofi. F.
Mercier: Research funding: Sanofi. R. de Wit: Consultant: Sanofi, Merck, Roche;
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Background: Platinum compounds have been tested in a larger number of mostly small
to medium sized clinical trials in molecularly unselected prostate cancer patients (pts).
Advances in castration-resistant prostate cancer (CRPC) molecular profiling have
shown that a significant proportion of pts harbor DNA repair defects, which may serve
as predictive markers for sensitivity to platinum agents. Our aim was to evaluate the
antitumour activity of platinum agents in a contemporaneous mCRPC cohort with or
without DNA repair defects.
Methods: International, multicenter retrospective database project in 14 centers world-
wide. Pts with mCRPC treated with a platinum agent were included. Pts with primary
pure small cell carcinoma and/or insufficient outcome data were excluded. For antitu-
mour activity PSA levels at baseline, after 4-, 8- and 12-weeks of therapy (tx) were ana-
lyzed as well as soft tissue response and duration of platinum-based chemotherapy.
Overall survival (OS) was analyzed by Kaplan Meier method.
Results: A total of 167 pts have been included in this analysis, 33 (20%) received plati-
num monotherapy, 134 (80%) a platinum combination therapy. Carboplatin was used
in 140 (84%), cisplatin in 26 (16%) of pts. Combination tx with etoposise was used in
45 (27%), paclitaxel in 35 (21%) and docetaxel in 28 (17%) of pts. At start of platinum
tx median age was 68 years, median PSA 78 ug/l, median ALP 185 U/l, median hemo-
globin 103 g/l. The metastatic sites at start of platinum therapy were: bone 84%, lymph
node 59% and visceral 60%. Outcome data by DNA repair defect status are summar-


















N (%) N (%) N (%)
PSA decline 50% 13/32 (41) 8/23 (35) 24/73 (33)
Soft tissue response (PR/CR) 9/32 (28) 7/29 (24) 16/48 (33)






(IQR 1.4 – 4.6)
3.5m
(IQR 1.4 – 4.6)
OS from start of platinum
therapy (m, IQR)
9.1m





Conclusions: In this retrospective analysis of a contemporary cohort of men with
mCRPC and poor prognostic characteristics platinum-based treatment seems to have
significant anti-tumor activity irrespective of DNA repair status. Comparison of sub-
groups is limited by small sample size. Updated analyses will be presented.
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Background: Bone metastases are common in CRPC patients and these patients (pts)
are at risk for symptomatic skeletal related events (SSE). Bone directed therapy and
early initation of a life-prolonging drug (LPD) therapy can prevent or prolong time to
SSEs. The objective is to evaluate whether delay in LPD has adverse outcome in CRPC
pts and a shorter SSE-free interval.
Methods: CAPRI is an investigator-initiated, observational study in 20 hospitals in the
Netherlands. All treated CRPC pts are retrospectively included in subgroups based on
type of first line treatment: LPD (docetaxel, abiraterone, enzalutamide or radium-223)
or non-LPD (other drugs as anti-androgens, prednisone). SSEs are defined as the
occurrence of either radiotherapy (RT) to the bone, surgery to the bone, pathological
fracture or spinal cord compression (SCC).
Results: 1,618 pts were included in this analysis. Median follow-up was 26 months
(IQR 15-39). 466 (29%) were treated with LPD (mostly docetaxel 15%) and 1,152
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(71%) with non-LPD (mostly bicalutamide 62%) in first line. In the non-LPD sub-
group, LPD was postponed in 712 patients. The LPD subgroup had frequent bone
metastases, worse ECOG and, higher LDH, ALP and PSA at the start of first line ther-
apy. 36% of all patients experienced a SSE during follow-up (32% RT to the bone, 4%
surgery to the bone, 4% pathological fracture and 6% SCC). There was a small differ-
ence in total SSEs between subgroups (39% for LPD vs 35% for non-LPD, p¼ 0.064).
Median SSE-free survival was 13.0 vs 21.2 months for LPD and non-LPD respectively
(HR 1.626, p¼ 0.007). Correction for prognostic factors showed that type of first line
therapy (LPD/non-LPD) was not associated with SSE-free survival (HR 1.021,
p¼ 0.817). Worse ECOG and presence of bone metastases were significant predictors
for worse SSE-free survival.
Conclusions: Approximately 40% of CRPC-patients developed a SSE during follow-
up. Worse patient and disease characteristics probably influenced timing of LPD. These
factors were also related with worse SSE-free survival. Delay in the initiation of a LPD at
castration-resistant state does not appear to influence outcome related to time-to-SSE.
Clinical trial identification: The CAPRI study is registered in the Dutch Trial Registry
as NTR3591.
Legal entity responsible for the study: Institute for Medical Technology Assessment,
Erasmus University Rotterdam.
Funding: The CAPRI registry was funded by Sanofi-Aventis Netherlands B.V., Janssen-
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Background: Androgen levels are associated with overall survival (OS) in mCRPC. Doc
impairs microtubules and has AR inhibitory effects. This analysis evaluates change in
androgen levels (Testosterone (T), Androstenedione (A) and DHEA (D) and outcome
in Doc-treated mCRPC patients.
Methods: Data from 1,050 men treated on CALGB 90401 with Doc, prednisone and
either B or placebo were used. Pre-treatment, 6 week and progression serum assays for
T, A and D were performed via tandem Liquid Chromatography-Mass Spectrometry
(LC-MS/MS). Ratio of change in androgen (6 week value /baseline value) was calcu-
lated. Decline was further evaluated as high or low (> or<median decline for all
patients). The logistic regression and proportional hazards models were used to assess
the prognostic significance of changes in T, A, and D in predicting PSA response, PFS
and OS adjusting for known prognostic factors.
Results: Median values for baseline T, A, and, D were 1.0, 13.5 and 8.1, ng/dL respec-
tively, while androgen levels at 6 weeks were 0.64, 7.0 and 6.8, ng/dL respectively. At 6
weeks a decline in all three androgens was observed. The ratio of 6weeks/baseline in T,
A and D were 0.93, 0.56 and 0.86, respectively. There was interaction between levels of
T decline and treatment arm (p-value¼0.047). Among 291 patients with high levels of
T decline, those who also received B were more likely to experience a 50% decline in
PSA (87%) compared to those who did not receive B (67%,). Associations between
androgen decline and PFS were NS. In multivariable analysis adjusting for prognostic
factors, the hazard ratio (HR) for OS demonstrated that decline in T at 6-weeks/base-
line was associated with longer OS, HR 1.02 (95% CI 1.01 ,1.03 p¼ 0.001). Median OS
for low T change (ratio>¼0.93) is 20.9 mos vs 26.3 mos for high T change (<0.93).
Conclusions: Patients treated with Doc who experience a greater drop in T on therapy
experience a significantly longer OS and higher rate of PSA decline but no effect on
PFS. B and androgen decline may confer interacting beneficial effects. Data are consis-
tent with the favorable prognostic significance of higher serum androgens in the CRPC
setting and reflecting the potential effect of Doc on AR signalling.
Clinical trial identification: NCT00110214.
Legal entity responsible for the study: Alliance for Clinical Trials in Oncology.
Funding: National Cancer Institute: R21 CA195424-01, U10CA180821, U10CA180882.
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Background: Cabazitaxel (CAB) has been shown in the TROPIC trial to improve over-
all survival (OS) in mCRPC patients after docetaxel (DOC). However clinical trial pop-
ulations may not reflect the real world population. The objective is to compare patient
characteristics and outcome of CAB within clinical trials and in standard of care (SOC)
from data extracted from the CAPRI registry.
Methods: CRPC pts treated with CAB directly after DOC, before 1-1-2017, either
within a clinical trial or as SOC were retrospectively identified and followed to 1-1-
2018. For multivariable analyses, missing values were imputed by multiple imputation
using the Monte Carlo Markov Chain method.
Results:
Table: 817P Baseline characteristics at start cabazitaxel (baseline
period defined as 42 days before to 7 days after start of cabazitaxel).
Total percentages may
Age (years) Median (IQR)
75 years (%)
68 (64-72) 17 67 (64-72) 13 0.502
Period on ADT (months)
Median (IQR)
25 (18-37) 30 (19-45) 0.091
ALP (U/L) Median (IQR)
Missing (%)
222 (100-360) 18 192 (97-366) 11 0.799
PSA (ug/L) Median (IQR)
Missing (%)




7.1 (6.3-7.8) 17 7.7 (6.7-8.1) 11 0.029
LDH (U/L) Median (IQR)
Missing (%)
328 (252-504) 26 268 (209-397 14) 0.010
ECOG performance (%) 0 1
>1 Missing
16 49 9 27 23 56 3 17 0.186
Visceral disease (%) No Yes
Missing
29 19 52 45 11 44 0.038
Opioid use (%) No Yes
Missing
23 28 50 41 27 33 0.140
Symptoms (%) No Yes
Missing
6 78 16 17 72 11 0.033
Docetaxel cycles Median
(IQR) Missing (%)
7 (5-10) 1 10 (7-10) 3 0.002
Time since last docetaxel
dose (months) Median
(IQR) <6 months (valid
%) Missing (%)
2.2 (0.9-4.7) 86 5 3.9 (2.0-6.0) 74 5 0.001
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